Welcome to Investor Relations

Abbisko Cayman Limited is a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since our inception, we have established a robust in-house R&D engine underpinned by our outstanding discovery team and multi-dimensional discovery platform. Leveraging strong discovery capabilities, we have strategically designed and developed a rich pipeline of 14 programs focused on oncology, including five assets at clinical stage.

Abbisko to present updated Phase Ib clinical results of Pimicotinib (ABSK021)in patients with advanced TGCT at the 2023 ASCO annual meeting
28 May 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that the updated results of Phase Ib study of CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor (“TGCT”), will be presented at the 2023 American Society of Clinical Oncology (“ASCO”) annual meeting held in Chicago, USA from June 2 to June 6, 2023.
Abbisko Therapeutics Completes the First Patient Dose in Global Phase III Trial of CSF-1R Inhibitor – Pimicotinib(ABSK021)
27 April, 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”hereafter) today announced first patient dosing of “A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor” in Beijing Jishuitan Hospital.
Abbisko presents 5 research results at the 2023 AACR Annual Meeting
Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting.
  • {{item.calendar_date.substr(8,2)}}
    {{item.meeting_time}} {{item.address}} {{item.address}}

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号